According to a regulatory filing, out earlier on Tuesday, Amarin entered into a Settlement Agreement on December 26 with Health Net that resolves previously disclosed patent infringement litigation in the U.S. District Court in Delaware. The specific terms of the settlement are confidential. The Company is pleased with the outcome and believes entering into the Settlement Agreement will provide significant value in the market with payors. The Company will continue to vigorously defend its intellectual property rights related to VASCEPA.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AMRN:
- Amarin Announces VAZKEPA® (icosapent ethyl) Receives Regulatory Approval in Switzerland
- Amarin announces VAZKEPA receives regulatory approval in Switzerland
- Amarin Announces VAZKEPA® (icosapent ethyl) Approved by the Therapeutic Goods Administration (TGA) in Australia
- HLS Therapeutics highlights data on RESPECT-EPA study
- Amarin highlights key data presented at AHA 2022 on VASCEPA/VAZKEPA
